|
Oops, make that 33% increase. Never was very good at math. I have two neighbors that have a huge Radiation Oncology Practice together. One was telling me that the standard for treatment of bladder cancer in the US was radical cystectomy (removal of the bladder altogether). Thus there is nothing to follow-up on in terms of monitoring for recurrence, (ie, NMP-22). In Europe however, they more commonly utilize radiation,sparing the bladder, making surveillance monitoring a neccesity (ie, NMP-22). He stated Europe is usually "ahead" of the US in terms of aggressiveness of treatment. I was glad to see the recent announcement of marketing alliances in Europe. Hopefully, radiation will soon be the standard of treatment in the US, sure to be a positive for Matritech. I also asked him to review the data on NMP technology, and he was very impressed, stating that this type of technology is definitely the direction medical science is heading. He was not aware of any comparable technology on the unseen horizon that would quickly obsolete NMP type testing. OK, enough grandstanding for now. Regards to all. Tim |
